Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
UPDATE 2-Novartis top lawyer exits in wake of Trump attorney deal
* CEO highlights pipeline strength, scope for bolt-on M&A (Adds CEO comments on strategy) 
Tags companyNews
From Reuters: Company News
Notable ETF Inflow Detected - XBI, AVXS, SRPT, ONCE
Symbols mentioned in this story: XBI, AVXS, SRPT, ONCE Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... 
Tags ETFs
From ETF Channel
Biotechs Soar After Big Trump Drug Price Speech- Mid-Caps Should Outperform
Biotechs soared Friday immediately after Trump’s much-anticipated new drug plan speech which was going to address high drug prices and potentially bring more government intervention. 
Tags Stocks / Equities ETFs Pharma/Biotech
From Blogs - TalkMarkets
Short Interest Declines 18.3% For AVXS
The most recent short interest data has been released for the 04/13/2018 settlement date, which shows a 681,577 share decrease in total short interest for AveXis Inc (AVXS), to 3,040,624, a decrease of... 
Tags Stocks
From Market News Video
Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week ... 
Tags Biotech AKRX Trading Ideas
From Benzinga
AveXis Reports First Quarter 2018 Financial and Operating Results
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial... 
From GlobeNewswire News Releases
Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags BPMC ACOR FDA
From Benzinga
Benzinga's Daily Biotech Pulse: Karyopharm's STORM Study, Inogen Rallies On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week ... 
Tags Top Stories SPHS NVS
From Benzinga
AveXis Provides Update on Proposed Acquisition by Novartis AG
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the... 
From GlobeNewswire News Releases
4 Huge Pharma Deals in 4 Months Is Just the Beginning
Here's what you need to know about the M&A mania spreading through big pharma. 
Tags AVXS SNY TKPYY
From Motley Fool
XBI, AVXS, ONCE, SRPT: Large Inflows Detected at ETF
Symbols mentioned in this story: XBI, AVXS, ONCE, SRPT Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... 
Tags ETFs
From ETF Channel
BRIEF-AveXis Announces First Patient Dosed In Phase 3 Trial Of AVXS-101 In Pre-Symptomatic SMA Types 1, 2 And 3
* AVEXIS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 TRIAL OF AVXS-101 IN PRE-SYMPTOMATIC SMA TYPES 1, 2 AND 3 Source text for Eikon: Further company coverage: 
Tags companyNews
From Reuters: Company News
AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the... 
From GlobeNewswire News Releases
AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will present initial results... 
From GlobeNewswire News Releases
Lifshitz & Miller LLP Announces Investigation of ADT Inc., AveXis, Inc., Connecticut Water Service, Inc., Edge Therapeutics, Inc., Fairmount Santrol Holdings, Inc., Oclaro, Inc., QuinStreet, Inc. and
From PR Newswire
Biotech And Pharma Stocks Await Q1 Earnings But Gene Editing Stocks Sell-Off
Biotech stocks held current levels but small caps and speculative stocks sold off with the XBI down 1%. 
Tags Healthcare Stocks / Equities Pharma/Biotech
From Blogs - TalkMarkets
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of AveXis, Inc. Buyout
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of AveXis, Inc. Buyout 
From Business Wire News Releases
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of AveXis, Inc. to Novartis for $218 Per Share is Fair to Shareholders – AVXS
Levi & Korsinsky, LLP reminds investors of an investigation into the fairness of the sale of AveXis 
From Business Wire News Releases
BRIEF-Adage Capital Partners GP LLC Reports 6.04 Percent Stake In Avexis
* ADAGE CAPITAL PARTNERS GP LLC REPORTS 6.04 PERCENT STAKE IN AVEXIS INC AS OF APRIL 11 - SEC FILING 
Tags companyNews
From Reuters: Company News
A tale of two deals—ahead of earnings, Biogen move perplexes
Biogen just announced a $1 billion deal, but it may not be enough to make investors happy. 
Tags Medical Products XBI Health/Care
From MarketWatch
NASDAQ:AVXS Investor Alert: Investigation of Takeover of AveXis, Inc
San Diego, CA -- (SBWIRE) -- 04/19/2018 -- An investigation was announced for investors, who currently hold shares of AveXis, Inc. (NASDAQ: AVXS), over the takeover of AveXis, Inc. 
From SBWire - Latest Press Releases
RM LAW Announces Investigation of AveXis, Inc.
RM LAW, P.C. is investigating potential claims against the board of directors of AveXis, Inc. ("AveXis" or the "Company") (NASDAQ: AVXS) concerning possible breaches of fiduciary duty and other... 
From PR Newswire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of AveXis, Inc. - AVXS
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating AveXis, Inc.... 
From PR Newswire
UPDATE 4-Novartis CEO feels heat on U.S. generics, Cosentyx drop
* Cosentyx sales drop since Q4 worries analysts (Adds comments from CEO, updates shares) 
Tags companyNews
From Reuters: Company News
AveXis to Present AVXS-101 Data at the Annual Meeting of the American Academy of Neurology
Includes Initial Data from SMA Type 1 Pivotal Trial (STR1VE) and 24-Month Follow-Up Data from Phase 1 Trial 
From GlobeNewswire News Releases
UPDATE 3-New Novartis CEO feels heat on U.S. generics business
* Cosentyx sales miss average analyst forecast (Recasts story to focus on Cosentyx, Sandoz; adds share performance) 
Tags companyNews
From Reuters: Company News
UPDATE 2-Novartis confirms 2018 targets as Alcon recovery gains steam
* Cosentyx sales miss analyst forecast (Adds analyst forecast) 
Tags companyNews
From Reuters: Company News
UPDATE 1-Novartis confirms 2018 targets as Alcon recovery gains steam
* Cosentyx sales miss analysts' forecast (Adds comment from CEO, details about drugs.) 
Tags companyNews
From Reuters: Company News
Noteworthy ETF Outflows: XBI, AVXS, ONCE, ICPT
Symbols mentioned in this story: XBI, AVXS, ONCE, ICPT Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These... 
Tags ETFs
From ETF Channel
Benzinga's Top Upgrades, Downgrades For April 18, 2018
Top Upgrades Morgan Stanley upgraded eBay Inc. (NASDAQ: EBAY) from Underweight to Overweight. eBay shares rose 6.25 percent ... 
Tags MRVL RIO Analyst Ratings
From Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.